Astrana Health, Inc.
NASDAQ:ASTHMedical - Care Facilities
+$1.03 today
- Market cap
- $1.47B
- Beta
- 0.94
- P/E (TTM)
- 63.3
- EPS (TTM)
- $0.62
Volume 0.52M
Average 0.51M
ASTH Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Astrana Health, Inc.NASDAQ: ASTH
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows in line with its trailing trend
Q1 FY2026 revenue of $965.1M rose 55.6% year over year, behind the +56.7% change in trailing-twelve-month revenue. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +40.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 8 analysts of $3.97B (+24.9%) for the fiscal year ending Dec 2026, a slowdown from the +56.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $965.1M+1.5% QoQ
- Last fiscal yearDec 2025
- $3.18B+56.4% YoY
- LTMMar 2026
- $3.53B+56.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +55.6% | +50.0% | -5.6 pp |
| 1 year | +56.4% | +24.9% | -31.5 pp |
| 3-year CAGR | +40.6% | +14.8% | -25.9 pp |
| 5-year CAGR | +11.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 3.18B USD
- Year-over-year change
- +56.4%
- 4-year CAGR
- +42.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.18B | +56.4% |
| FY2024 | 2024-12-31 | 2.03B | +46.7% |
| FY2023 | 2023-12-31 | 1.39B | +21.2% |
| FY2022 | 2022-12-31 | 1.14B | +47.8% |
| FY2021 | 2021-12-31 | 773.92M | — |
Revenue vs competitors
How ASTH compares with its peers on the latest reported figures
- ASTH's LTM Mar 2026 revenue of $3.53B is the 2nd highest of the 4 companies compared; the peer median is $2.36B.
- Its year-over-year change of +56.7% is the highest of 4, against a peer median of +24.1%.
- Over three fiscal years its annual growth of +40.6% compares with a peer median of +35.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $5.82B | -2.8% | +35.4% | |
| LTM Mar 2026 | $3.53B | +56.7% | +40.6% | |
| LTM Jun 2026 | $2.36B | +24.1% | +16.1% | |
| LTM Mar 2026 | $879.95M | +41.0% | +58.6% | |
| Peer median (excluding ASTH) | $2.36B | +24.1% | +35.4% | |
Competitors are the stored peer set for ASTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 773.92M | 1.14B | 1.39B | 2.03B | 3.18B |
| Cost of Revenue | 596.14M | 944.69M | 1.17B | 1.76B | 2.89B |
| Gross Profit | 177.77M | 199.48M | 214.96M | 271.39M | 295.78M |
| Gross Margin | 23.0% | 17.4% | 15.5% | 13.3% | 9.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 62.08M | 77.67M | 112.6M | 154.11M | 217.26M |
| Operating Expenses | 79.59M | 95.21M | 130.35M | 182.04M | 217.26M |
| Depreciation & Amortization | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M |
| EBITDA | 100.66M | 112.08M | 123.69M | 141.84M | 135.28M |
| EBITDA Margin | 13.0% | 9.8% | 8.9% | 7.0% | 4.3% |
| Operating Income | 98.18M | 104.27M | 84.61M | 89.35M | 78.53M |
| Operating Margin | 12.7% | 9.1% | 6.1% | 4.4% | 2.5% |
| Interest Income | 1.57M | 1.98M | 14.21M | 14.51M | 12.16M |
| Interest Expense | 5.39M | 7.92M | 16.1M | 33.1M | 49.93M |
| Other Income / Expenses | (20.43M) | (17.65M) | 5.23M | (8.53M) | (38.92M) |
| Income Before Tax | 77.75M | 86.62M | 89.84M | 80.82M | 39.61M |
| Pre-Tax Margin | 10.0% | 7.6% | 6.5% | 4.0% | 1.2% |
| Income Tax Expense | 31.69M | 40.88M | 31.99M | 30.89M | 15.53M |
| Net Income | 68.92M | 45.17M | 60.72M | 43.15M | 22.49M |
| Net Margin | 8.9% | 3.9% | 4.4% | 2.1% | 0.7% |
| EPS (Basic) | 1.57 | 1.00 | 1.30 | 0.91 | 0.46 |
| EPS (Diluted) | 1.52 | 0.99 | 1.29 | 0.90 | 0.46 |
| Weighted Avg Shares | 43.83M | 44.97M | 46.71M | 47.69M | 49.08M |
| Weighted Avg Shares (Diluted) | 45.4M | 45.6M | 47.07M | 48.22M | 49.37M |
Astrana Health, Inc.
NASDAQ:ASTH
Intrinsic Alpha fair value
Locked
Current Price
$29.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.